Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.commediarelations@travere.com Travere Therapeutics Reports First Quarter 2024 Financial Results FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511 new patient start forms (PSFs) for FILSPARI in Q1 2024; Total of 1,963 PSFs received since launch Net product sales of FILSPARI ...